We have located links that may give you full text access.
A recent institutional experience with renovascular hypertension.
American Surgeon 1996 March
During and 8-year period, 51 patients with renovascular hypertension were evaluated. Etiologies of renovascular disease included atherosclerosis 29 (57%), Takayasu's arteritis 11(22%), fibromuscular dysplasia six (11%), renal artery dissection two (4%), trauma two(4%¿ and aneurysm one (2%). Fifteen (29%) patients had bilateral renal artery disease, and 16 (31%) had associated chronic renal failure. Seven patients initially underwent percutaneous transluminal angioplasty, three of whom later required operative intervention for recurrent hypertension, and one required repeat angioplasty. Three patients had no further intervention. Forty-seven patients underwent surgical revascularization tailored to the angiographic and intraoperative findings. Procedures performed included 36 (55%) aortorenal bypasses; 12 (18%) endarterectomies; five (8%) ex-vivo reconstructions; three (4%) renal artery reimplantations; two (3%) other visceral artery-to renal (hepatic/splenic) reconstructions; one (2%) renal artery patch graft; and seven (10%) nephrectomies. Concomitant aortic replacement occurred in 20 cases. There were two deaths, and remedial operations for recurrent hypertension were required in three patients. The mean follow up was 12 months (range 6-45 months). Hypertension was cured in 25 (57%), improved in 14(32%), and unchanged in five (11%). Of the 16 patients with chronic renal failure, eight (50%) had a reduction in serum creatinine >10%. The etiology of renovascular hypertension is variable. Although transluminal angioplasty may be indicated in selected patients, surgical revascularization is usually necessary. A flexible operative approach to accommodate the variable patterns of renal artery disease optimizes surgical results. Renal revascularization may provide and improvement in excretory renal function.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app